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Interest remains in the origins of healthcare-associated infection (HAI). If we knew how 
many infections originated from hands; environment; equipment; air; visitors; or patients 
themselves, then infection prevention activities could be prioritised according to risk. The 
paper from Ellingson et al chooses to focus on the role of the environment by applying a 
quaternary ammonium organosilane to surfaces in two different hospitals.1 It describes the 
clinical and environmental impact of this coating in a medical ICU and two medical wards in 
Hospital A; and medical and neurological ICUs and transplant step-down unit in Hospital B. 
While there were notable differences between the two hospitals, the results suggest that 
surface bioburden, including pathogens, was significantly reduced, along with decreased 
rates of multidrug resistant organism (MDRO) bloodstream infections (BSI) and Clostridium 
difficile infections (CDI). 
At first sight, this seems like the study we have been waiting for, to seal the role of the 
environment in HAI. Healthcare surfaces serve as a reservoir for potential pathogens, which 
are able to survive for weeks in temperate surroundings.2 Pathogens may be controlled by 
cleaning and decontamination practices but these do not necessarily eliminate all risk. It is 
fair to say that replacing surfaces with antimicrobial products might offer an additional 
safeguard when there are cleaning deficits. Such coatings provide an alternative to the daily 
rigours of cleaning and could even temper the debate over how this should be done.3 But 
life is not that simple and delving into study methods uncovers some apposite concerns over 
missing detail and interpretation. To begin with, the coating is billed as ‘bactericidal’, when 
we know that many other microorganisms adhere to surfaces, namely spores, fungi and 
viruses. Quaternary ammonium compounds are generally inactive against CD spores; 4 so 
how does this coating decrease surface contamination and infection rates of C.difficile? The 
authors suggest that the coating generates an electric charge, which encourages adhesion 
potential for spores and makes them less likely to be aerosolized or transferred to other 
surfaces.5 This may well be the case but we need robust experimental investigation for all 
the relevant pathogens, including spores, which were absent from the reference provided.  
Is the coating active against the new-kid-on-the-block, Candida auris? 6 There were clear 
reductions in surface bacterial counts but no data on fungi. Since Trypticase Soy Agar 
supports fungal growth, should we assume that the counts were based on environmental 
bacteria, with fungal colonies excluded? This would have been technically difficult to 
perform so perhaps fungal colonies were indeed part of the overall surface count. There 
was no detail on the fungal contribution to MDRO-BSI data. 
However effective the coating might be on dispelling bioburden, there was still a necessity 
for it to be replenished at regular intervals throughout the study. A shelf life of 15 weeks is a 
very short time in the life of a hospital. Estates departments may not have the resources to 
be able to spray all selected sites in clinical areas every four months or so. Study sponsors 
would have absorbed the costs of the product, application and re-application for the study 
itself but there was no indication of initial and ongoing costs of neither the product nor its 
application for interested parties to compare. Infection control personnel (and managers) 
need to know that interventions provide cost-benefit. 
Such coatings are ineffective if applied to surfaces without prior cleaning and this was 
clearly described in the study. However, there were no assurances over any physical effects 
from the coating or its reapplication, such as discolouration of treated surfaces, or changes 
in texture, such as grittiness or stickiness from product build up.7 We also need to know 
whether the coating interacts with other fluids used in the healthcare environment, 
particularly for decontamination. There are many powerful disinfectants on the market, the 
components of which might react with the product to release substances that could be 
harmful. They may inactivate the coating or even strip it from its host surface. The product 
requires independent verification of activity against a full range of microbes as well as data 
on chemical composition and reaction following exposure to other compounds.  
What is the risk that environmental flora, including pathogens, could become tolerant to 
quaternary ammonium compounds during long term exposure? 8 This is particularly 
pertinent when the same, or similar, chemicals are also being used as disinfectants for 
routine cleaning. Sustained effects of the product, and indeed, any others that contain 
antimicrobial agents must be elucidated before widespread adoption in healthcare 
environments. The concern is that organisms evolve survival mechanisms when habitually 
exposed to a substance that could potentially damage or destroy them; these mechanisms 
may include the facility for antimicrobial resistance that could be transmitted to other 
environmental flora, including pathogens.8 
The study was not randomised so staff (and patients) would have known about the 
intervention and domestic staff would have witnessed the sampling procedures. Given that 
cleaners always react to environmental monitoring, they may have altered their delivery in 
order to preclude criticism.3 There might even have been the opposite effect, that of 
diminution of diligent cleaning if staff knew that the coating was capable of eliminating 
pathogens! The study design did not audit cleaning practices and therein illustrates a classic 
confounder to any study investigating environmental decontamination. 
Of course, cleaners are not the only staff segment that may have changed their practices in 
response to this study. There would have been other personnel in the vicinity whose 
behaviour might have been affected by application of an antimicrobial coating. This includes 
study personnel themselves, especially as there remains concern over industry involvement 
in healthcare research; bias is difficult to ignore and not always detectable.9 There is some 
sympathy towards companies trying to obtain recognition for new products but widespread 
acceptance should, and must, depend on quantity and quality of independent studies. 
While mentioned, no antimicrobial consumption data was presented and this represents 
another major confounder. Changes in antimicrobial prescribing could have facilitated most, 
if not all, the data presented in this paper.10 There were also inferences of changes in 
isolation policies and hand hygiene compliance, but nothing on outbreak occurrence, either 
before or during the study. Could the reduction in CDI, in particular, represent reversion to 
the norm following increased incidence? Or, was the lack of effect in Hospital B due to 
undetected cross-infection? It would have been helpful to have seen an appendix containing 
detail on MDRO-BSI for both hospitals.  
Definitions of BSI do not always correctly identify ‘infection’; nor presence of quoted 
organism in the blood stream (e.g. contamination during collection or processing); nor 
legitimate healthcare contribution (e.g. present but undetected or masked before hospital 
admission).11 MDROs themselves encompass microorganisms that originate from the 
healthcare environment, i.e. the proportion that might be repelled by an antimicrobial 
coating, but there are others that come from endogenous reservoirs such as skin, mucous 
membranes and gastrointestinal system.12 These are independent of any impact elicited by 
an antimicrobial surface coating. Indeed, direct transmission of MDROs from the air; or from 
another patient or uncoated surface, such as ward items or equipment; laundry; visitors; 
consumables and gifts, would bypass any generic coating of selected surfaces. This then 
begs the question, are the data presented in this paper biologically plausible?  
Six years ago a study was published suggesting that copper coated surfaces could halve the 
rate of HAI.13 The study outcomes were complex, the reporting intentionally selective, and a 
final evaluation that contradicted biological plausibility.14 According to Weinstein, up to 60% 
acquired infection is endogenous, with 20% attributed to staff hands and another 20% 
originating from exogenous sources, including environment.12 This proportion is supported 
by a recent study using whole genome sequencing to track one pathogen (Staphylococcus 
aureus) in an ICU.15 Systematic screening of patients, surfaces, air and staff hands found that 
59% transmission events occurred between colonised patients and their own body sites, i.e. 
endogenous transmission, including BSIs. There were 30% transmission events involving the 
environment, including air, but only 12% that linked patients directly with hand-touch sites.  
In short, the copper study conclusion was contested because the magnitude of reduction 
assumed to relate directly to the environment was not biologically feasible.14 Now we have 
a similar study, suggesting that chosen HAI indicators (MDRO BSIs and CDI) decreased by 
over a third after some, but not all, surfaces were coated with an antimicrobial agent. Are 
surface pathogens ultimately responsible for more than a third invasive HAIs? How many 
environmental pathogens find their way into a patient after a minimum of 2 days in 
hospital, specifically gut and blood stream? 12, 16,17 
We should put it to the authors that their findings are biologically implausible, given the 
detail supplied. But, we remain intrigued; hopeful, and mindful of future studies, designed 
to test the aims expounded in this paper. It is not impossible that an antimicrobial coating of 
some type will become standard for all healthcare surfaces one day. One wonders what our 
domestic staff will do then. 
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